The Implication of N-Acetylglucosaminyltransferase V Expression in Gastric Cancer

Hai Tian a Eiji Miyoshi b Naomasa Kawaguchi a Mohammed Shaker a Yasuhiro Ito a Naoyuki Taniguchi c Masahiko Tsujimoto d Nariaki Matsuura a

Departments of Molecular Pathology and Biochemistry, Graduate School of Medicine and Health Science, and Department of Disease Glycomics, Research Institute for Microbial Diseases, Center for Advanced Science and Innovation, Osaka University, Suita, and Department of Pathology, Osaka Police Hospital, Osaka, Japan

Introduction

Gastric cancer is the second most common cause of cancer-related mortality worldwide and its incidence is raised in Japan, China and South America [1]. Although most patients with early gastric cancer can be cured with minimally invasive treatment, the prognosis of patients with advanced gastric cancer remains poor since many patients develop a recurrence with peritoneal dissemination or liver metastases [2]. However, since factors which may contribute to metastasis of gastric cancer have been elucidated [3, 4], we aimed to look for a marker which is able to predict the metastatic potential of advanced gastric cancer and to identify patients with a poor prognosis who are prone to recurrence of gastric cancer.

Key Words
Gastric cancer · GnT-V · Immunohistochemistry · Metastasis · Prognosis, gastric cancer

Abstract

Objective: N-acetylglucosaminyltransferase V (GnT-V) is a key enzyme that catalyzes β1-6 branching of N-acetylglucosamine on N-glycan of cell proteins, some of which are linked with metastasis. GnT-V expression was studied immunohistochemically in gastric cancer to compare clinicopathological parameters and evaluate the role of GnT-V in the prognosis of gastric cancer. Methods: Immunohistochemistry was carried out to detect GnT-V expression in 50 advanced gastric cancer tissues where the depth of invasion exceeded the subserosa, and the relationship between GnT-V expression and various clinicopathological factors, including survival, was analyzed. Results: GnT-V was expressed in 23 (46%) gastric cancer tissues. GnT-V expression was significantly correlated with lymph node metastases, peritoneal dissemination and liver metastases, respectively (p = 0.005, p = 0.013 and p = 0.023). Patients with GnT-V-positive gastric cancer had a significantly shorter survival than those without GnT-V expression (5-year survival rate: 31.2 and 54.4%, respectively; p = 0.045). Conclusion: GnT-V expression is correlated with a poor prognosis in gastric cancer patients due to metastases.

Copyright © 2008 S. Karger AG, Basel

Received: January 22, 2008
Accepted after revision: March 31, 2008

Prof. Nariaki Matsuura
Department of Molecular Pathology
Graduate School of Medicine and Health Science, Osaka University
1-7 Yamada-oka, Suita, Osaka 565-0871 (Japan)
Tel. +81 6 6879 2591, Fax +81 6 6879 2595, E-Mail matsuura@sahs.med.osaka-u.ac.jp
The increase in GnT-V activity and its cell surface products results from increased transcription driven by activation of the Ras-Ets and protein kinase B signaling pathway [10–12]. Some studies have demonstrated that increased expression of GnT-V in breast and colorectal cancer correlates with distant metastases and a poor prognosis [13–15]. In contrast, it does not correlate with a poor prognosis in hepatoma and non-small cell lung cancer [16, 17]. Hepatoma cells with high GnT-V expression, e.g. HuH7 and HepG2 cells, showed no metastasis in studies using athymic mice [18]. These results indicate the biological significance of GnT-V is apparently different for each type of cancer. It was also reported that gastric cancer cells in which the GnT-V gene was transduced overexpressed GnT-V; GnT-V transfectants injected into the abdominal cavity of nude mice resulted in increased metastasis formation 1 month later [19]. However, the relationship between GnT-V expression and metastasis and prognosis in human gastric cancer tissue is still unknown.

**Materials and Methods**

**Tissue Specimens and Patient Follow-Up**

Tissue specimens of gastric cancer were obtained from 50 patients (35 men and 15 women) who had undergone surgery at the Osaka Police Hospital in 1992–1996. In order to evaluate prognostic implications, more advanced cases with gastric cancer exceeding the subserosa were analyzed. There are 29 cases with subserosal invasion, 20 cases with penetration to the serosa without invasion of adjacent structures, and 1 case with invasion to adjacent structures. The patients were followed up in the outpatient clinic of the hospital for >60 months postoperatively. For immunohistochemical study, the tissues were fixed with 10% phosphate-buffered formalin, followed by preparation of paraffin-embedded blocks. In 50 patients, 8 cases metastasized to the peritoneum, 6 cases to the liver, 1 case to both peritoneum and liver, and 1 case metastasized to the spleen during the follow-up period after operation. The conventional clinicopathological parameters and TNM stage, followed by the criteria of the 5th International Union against Cancer TNM classification published in 1997 [20], were compared with GnT-V expression.

**Immunohistochemistry**

**Antibody.** For immunohistochemical evaluation, a mouse monoclonal antibody against recombinant human GnT-V, which was generated in the Department of Biochemistry, Osaka University Graduate School of Medicine [15], was prepared.

**Method.** Immunohistochemical studies for GnT-V were performed with the avidin-biotin complex method [21]. Briefly, tissue samples were prepared as 3-μm-thick sections from paraffin-embedded specimens, followed by deparaffinization and blocking endogenous peroxidase activity with 0.3% hydrogen peroxide in methanol for 15 min. After being washed in 0.01 mmol/l phosphate-buffered saline (PBS) three times, 10% bovine serum was added for 30 min to block nonspecific binding at room temperature. A primary antibody (anti-GnT-V) was applied to sections at a concentration of 1:100 and incubated at 4°C overnight. After being washed 3 times in PBS, secondary antibody, biotinylated anti-mouse immunoglobulin (Amersham, London, UK), was applied for 30 min at a concentration of 1:200. After rinsing in PBS, peroxidase-conjugated streptavidin (at a concentration of 1:200; DAKO, Glostrup, Denmark) was incubated for 30 min. The peroxidase reaction was carried out in 0.05 mol/l Tris-HCl (pH 7.6) containing both 0.02% 3,3-diaminobenzidine tetrahydrochloride and 0.03% hydrogen peroxide for 5 min. The tissue sections were counterstained with hematoxylin.

**Immunohistochemical Evaluation.** The results for GnT-V expression in gastric cancer were divided into two groups according to the evaluation of the former studies: + (≥10% carcinoma cells expressed GnT-V) and – (<10% carcinoma cells or no carcinoma cells expressed GnT-V) [16]. The staining sections were examined by two independent observers without prior knowledge of the clinical status of the patients.

**Results**

**GnT-V Expression in Gastric Cancer**

Among 50 gastric cancers, GnT-V was expressed in both cancer cells and non-cancerous mucosal epithelial cells of 23 patients. The representative positive cases are shown in figure 1. The distribution of GnT-V-expressing cancer cells varied: in some cases, GnT-V-positive cancer cells were diffusely scattered, while GnT-V was heterogeneously disseminated in others. Though advanced gastric cancers penetrating the subserosa were examined, several cases developed multiple cancers including early cancers, and GnT-V was also detected in mucosal or submucosal gastric cancer. Thus GnT-V expression in gastric cancer cells was apparently not associated with the areas where cancer cells were present. In all GnT-V-positive cases, GnT-V was also expressed in normal gastric foveolar epithelium adjacent to gastric cancer, while GnT-V was not expressed in intestinal metaplasia. The intensity of GnT-V expression gradually decreased with increasing distance from cancer cells, but we could not conclude whether these patterns were implicative or not since we did not test normal gastric tissues without can-
cer cells. Two cases demonstrated GnT-V expression in normal mucosa but not in cancer cells. In subcellular localization, GnT-V was diffusely scattered in the cytoplasm of most gastric cancer cells (fig. 1b–d). On the other hand, some gastric cancer cells showed GnT-V expression in the Golgi area as well as in normal epithelium (fig. 1a).

**Relationship between GnT-V Expression and Clinical Parameters**

We analyzed the relationship between GnT-V expression and various clinicopathological features (table 1). There were significant associations between GnT-V expression and lymph node metastases, peritoneal dissemination and liver metastases, respectively (p = 0.036, p = 0.013 and p = 0.023). In addition, GnT-V expression and curability were correlated (p = 0.014). However, GnT-V expression was not associated with other parameters, e.g. sex, tumor size (maximal diameter), tumor location, histological differentiation, lymphatic invasion and vascular invasion.

**Relationship between GnT-V Expression and TNM Staging**

We summarized the relationship between GnT-V expression and TNM staging factors in table 2. There were significant correlations between GnT-V expression and N factor (lymph node metastasis), M factor (distant metastasis) and TNM stage, respectively (p = 0.0054, p = 0.0018 and p = 0.0043), but T factor (tumor depth) was not associated with GnT-V expression. These results are consistent with those for clinicopathological parameters.
GnT-V Expression in Gastric Cancer

We investigated the prognostic value of GnT-V expression in 50 patients of gastric cancer who had undergone surgery. Five-year overall survival for patients with GnT-V-negative expression was 54.4%. In contrast, 5-year overall survival for patients with GnT-V-positive expression was only 31.2% (fig. 2). There was a significant correlation between 5-year survival and GnT-V expression \( p = 0.045 \). Twenty-two patients had pStage I–II gastric cancer: in 2 of 5 patients (40%) with GnT-V-positive expression survival was \( >5 \) years compared with only 1 of 17 patients (5.9%) with GnT-V-negative expression. In the analysis of the relationship between the 5-year survival rate and GnT-V expression, patients with GnT-V-positive gastric cancer had a significantly shorter survival than GnT-V-negative cases (53.3 and 92.9%, respectively; \( p = 0.026 \); fig. 3). For those with pStage III–IV gastric cancer, the survival rate was not significantly different between GnT-V-positive and -negative patients.

### Discussion

In the current study, we demonstrated that GnT-V expression was significantly correlated with a poor prognosis as well as metastases in advanced gastric cancer. Expression of GnT-V was reported to be significantly correlated with a poor prognosis in breast and colorectal cancer \[13–15\]. It was also mentioned that there was a significant association between GnT-V expression and poor prognosis in colon cancer, being mainly attributable to the poor prognosis in pStage II colon cancer \[15\]. Also, in our study cohort, the survival rate of pStage I–II gastric cancer cases was significantly affected by the expression of GnT-V, while there was no difference between the survival rate and GnT-V expression in pStage III–IV gastric cancer.
cancer. Our result was consistent with a previous report in colorectal cancer. Our immunohistochemical study also showed strong correlation of GnT-V expression with lymph node and distant metastases, including liver metastasis and peritoneal dissemination, and these strong associations appeared to influence a poor prognosis.

GnT-V is a key enzyme in the processing of multiantennary N-glycans during glycoprotein biosyntheses, including cell surface and secreted glycoproteins associated with cancer metastasis. GnT-V, for example, has been known to regulate integrin function through its glycosylation. Cells transfected with the GnT-V gene have been shown to have reduced adhesion to extracellular matrix proteins, such as collagen or fibronectin, and this reduced adhesion has been associated with glycosylation of integrins α5 and β1 [12, 22]. Increased β1-6 branched N-glycan on β1 integrin reduced α5β1 integrin clustering and stimulated migration of human fibrosarcoma cells in vitro [22]. This phenotype favors the migration of cancer cells in the early steps of metastasis. Furthermore, GnT-V stabilizes and elevates enzymatic activity of a membrane-type serine protease, matriptase [19]. Matriptase activates hepatocyte growth factor, and urokinase-type plasminogen activator as well as matriptase can directly degrade extracellular matrix proteins. Since both hepatocyte growth factor and urokinase-type plasminogen activator are involved in cancer invasion, activation of matriptase by GnT-V is also advantageous for the early steps of the metastatic process. On the other hand, GnT-V is involved in the later steps of distant metastases of cancer cells. Sialyl Lewis X is a ligand for E-selectin, which is attached to the N- and O-termini of glycans. E-selectin mediates the process by which cancer cells attach to endothelial cells [23, 24]. In addition, sialyl Lewis X was correlated with metastatic potency in human cancer, including colon cancer, gastric cancer and pancreatic cancer [25–28]. In addition, expression of sialyl Lewis X was induced by GnT-V expression in colon cancer cells [28]. Moreover, GnT-V itself induced the release of fibroblast growth factor-2 from heparan sulfate proteoglycan, leading to angiogenesis and metastasis in secondary organs [29]. These results suggested that GnT-V influenced the function of various glycoproteins which play important roles in the process of metastasis, and total increased activity of those glycoproteins might induce different types of metastasis: lymph node, peritoneal and liver metastasis.

GnT-V was expressed not only in gastric cancer cells but also in non-cancerous gastric epithelium, including remote gastric mucosa as well as adjacent mucosa. In a previous report, GnT-V was expressed in different normal tissue, including the mouse stomach [30]. β1-6 N-glycan synthesized by GnT-V was expressed in epithelial cells of the human stomach [31]. Since immunohistochemical GnT-V expression was apparently lower in normal epithelium, and subcellular localization in normal epithelium is different from that of gastric cancer cells,
the glycoproteins affected by GnT-V might be different. Previous studies have shown that increases in GnT-V expression after oncogenic transformation are most likely caused by direct effects on the GnT-V promoter by the Ets family of transcriptional activators, which are upregulated by a cellular proliferation signaling pathway [32], supporting our results of increased GnT-V expression in gastric cancer regions compared with normal gastric mucosa. Because the signaling pathway was induced by some growth factors and cytokines, the growth factors and cytokines secreted by cancer cells might influence the expression of GnT-V in non-cancerous tissue surrounding the gastric cancer region. Further investigation will be required for the implication of GnT-V in normal and gastric cancer.

In the current study, GnT-V expression, which was detected by immunohistochemistry, was a valuable factor predicting prognosis after curative resection of gastric cancer. Future advances in diagnostic techniques may facilitate the earlier detection of metastases. Most gastric cancers of pStage I–II are potentially curable by adequate treatment. Identification of specific indicators of invasive or metastatic potential within the primary tumor at the time of surgery (GnT-V expression as shown in the current study) would allow for a better prognostic stratification and more effective treatment of gastric cancer patients. In particular, the stratification of a subset of pStage I–II gastric cancer patients into those with either a favorable or a poor prognosis may be clinically important.

Though treatment of advanced gastric cancer mainly depends on surgical resection, adjuvant therapy has widely been tested in the treatment of gastric cancer. In the USA, the use of postoperative chemoradiation in gastric cancer is considered standard of care now. A significant benefit for overall and disease-free survival was demonstrated for patients with chemoradiotherapy after gastric resection [33]. Recently, decreased $\beta_1$-$\delta$-N-acetylglucosamine ($\beta_1$-$\delta$GlcNAc) branching in N-glycan of $\alpha_3$$\beta_1$-integrin was associated with cisplatin resistance in squamous cell cancer [34]. The N-glycan structure of $\alpha_3$$\beta_1$-integrin can be changed by down- or upregulation of glycosyltransferases [12, 35]. Possibly, GnT-V will be used as adjuvant to radiochemotherapy against cisplatin-resistant tumor cells, including gastrointestinal cancer.

In conclusion, the biological character of GnT-V critical for the development and prognosis of cancer, and differs among various cancer types, depending on the biological function of the target substrate glycoprotein, which can vary among organs and tissues. In the present study, we demonstrated that GnT-V expression is correlated with distant metastases and a poor prognosis in gastric cancer. The evaluation of the prognosis of postoperative patients of gastric cancer by immunohistochemical assessment of GnT-V may be beneficial regarding future patient management, and GnT-V may also be targeted in the treatment of metastases.

Acknowledgement

We thank Ms. Kumiyo Hirai for her technical support.

References

294 Pathobiology 2008;75:288–294

Tian/Miyoshi/Kawaguchi/Shaker/Ito/Taniguchi/Tsujimoto/Matsuura


